ArticleAdvances in therapy2026
Beyond Single-Class Therapy: Real-World Combined Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) exert complementary metabolic effects and have independently demonstrated cardiovascular benefits in individuals with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD). However, despite growing evidence suggesting potential additive benefits in high-risk populations, real-world data on dual therapy remain limited. This study aimed to identify clinical factors associated with the use of combined GLP-1RA/SGLT2i therapy in routine practice.
methodsThis retrospective observational study included 202 adults with T2DM and established ASCVD admitted to a tertiary care hospital between November and December 2025. Patients were categorized according to their pre-admission outpatient regimen into four groups: neither therapy, GLP-1RA only, SGLT2i only, and combined therapy. Clinical characteristics and comorbidities were recorded at admission. Multinomial logistic regression analysis was performed to identify factors associated with treatment allocation.
resultsAmong 202 patients, 54.5% were not receiving either class, 10.9% were treated with GLP-1RA only, 21.3% with SGLT2i only, and 13.4% with both. In adjusted analyses, combined therapy was independently associated with younger age [odds ratio (OR) 0.89 per year, 95% confidence interval (CI) 0.84-0.95, p < 0.001], presence of heart failure (OR 9.64, 95% CI 2.65-35.04, p < 0.001), and insulin use (OR 10.99, 95% CI 3.12-38.72, p < 0.001). Chronic kidney disease and polyvascular disease were not associated with dual therapy use.
conclusionIn this real-world cohort of patients with T2DM and ASCVD, more than half were not receiving a cardioprotective glucose-lowering therapy. Combined GLP-1RA/SGLT2i therapy was infrequently prescribed and was associated with selected clinical characteristics rather than overall cardiorenal risk burden. These findings highlight an opportunity to better align treatment strategies with a comprehensive risk-based approach.
Indexed as
Identifiers
42423950What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.